Watch Live

Tweet TWEET

NPS Pharmaceuticals’ President and CEO Dr. Francois Nader Receives Ernst & Young Entrepreneur Of The Year® 2013 Award in New

  NPS Pharmaceuticals’ President and CEO Dr. Francois Nader Receives Ernst &
  Young Entrepreneur Of The Year® 2013 Award in New Jersey

      -- Award recognizes entrepreneurial excellence in life sciences --

Business Wire

BEDMINSTER, N.J. -- June 14, 2013

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company
pioneering and delivering therapies that transform the lives of patients with
rare diseases worldwide, today announced that president and chief executive
officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of
The Year^® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader
was presented with the award at a special gala event on June 13 at the Hyatt
Regency New Brunswick, New Jersey.

“I’m truly honored to accept this award and be recognized by Ernst & Young
among the successful entrepreneurs in New Jersey,” said Dr. Nader. “It’s an
exciting moment for the entire NPS team, which has achieved so much and works
so hard each and every day to bring innovative therapeutics to patients
suffering from rare diseases around the world.”

Dr. Nader joined NPS in 2006 and was appointed president and chief executive
officer in March 2008. He led the company’s transformation into a global
commercial-stage biopharmaceutical company focused on bringing innovative
treatments to patients with rare diseases. During his tenure, Dr. Nader
created a values-driven culture-by-design that contributed to NPS being named
as one of the top 100 companies to work for in New Jersey for two consecutive
years. Earlier this year, NPS launched Gattex® (teduglutide [rDNA Origin]) for
injection, its first medication approved by the U.S. Food and Drug
Administration (FDA) and the European Commission. The company is now preparing
to seek approval for its second orphan drug candidate, Natpara® (recombinant
human parathyroid hormone (rhPTH [1-84]). In March, Dr. Nader established NPS
as a global commercial rare disease company by reacquiring the worldwide
rights to its two lead drugs from Takeda GmbH. During Dr. Nader's five-year
tenure as president and chief executive officer, his focus on value creation
has significantly contributed to a seven-fold increase in the company's market
capitalization.

As a New Jersey award winner, Dr. Nader will next compete at the national
level. Award winners in several national categories, as well as the National
Ernst & Young Entrepreneur Of The Year Overall Award winner, will be announced
at the annual awards gala in Palm Springs, California on November 16. The
awards are the culminating event of the Ernst & Young Strategic Growth
Forum^®, the nation’s most prestigious gathering of high-growth,
market-leading companies.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards
are nationally sponsored by SAP America and the Ewing Marion Kauffman
Foundation.

In New Jersey, local sponsors include PNC Bank, DLA Piper, Merrill
Corporation, Morgan Lewis, Empire Valuation Consultants, Scherzer
International, SolomonEdwardsGroup, Cresa NJ, Gibbons, Murray Devine, New
Jersey Technology Council, NJBIZ, WithumSmith+Brown.

About Ernst & Young’s Entrepreneur Of The Year^®

Ernst & Young’s Entrepreneur Of The Year is the world’s most prestigious
business award for entrepreneurs. The unique award recognizes the significant
contributions of entrepreneurs who inspire others with their vision,
leadership and achievement.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering
therapies that transform the lives of patients with rare diseases worldwide.
The company’s lead product, teduglutide (Gattex® (U.S.)/Revestive® (EU)) is
for adult Short Bowel Syndrome (SBS). NPS is also developing Natpara®
(recombinant human parathyroid hormone or rhPTH[1-84]) for the treatment of
adult hypoparathyroidism and subject to the resolution of certain
manufacturing issues, expects to submit its Biologic License Application (BLA)
to the FDA in the second half of 2013.

NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and
NPSP795, with potential application in rare disorders involving increased
calcium receptor activity, such as autosomal dominant hypocalcemia with
hypercalciuria (ADHH). NPS complements its proprietary programs with a
royalty-based portfolio of products and product candidates that includes
agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa
Hakko Kirin. Additional information about NPS is available through its
corporate website, http://www.npsp.com.

“NPS,” “NPS Pharmaceuticals,” “Gattex,” “Natpara,” “Preotact,” and “Revestive”
are the company's trademarks.

Disclosure notice

Statements made in this press release, which are not historical in nature,
constitute forward-looking statements for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. These statements are
based on the company's current expectations and beliefs and are subject to a
number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. Forward
looking statements include, but are not limited to, statements concerning our
future financial performance. Risks associated to the company's business
include, but are not limited to, the risks associated with any failure by the
company to successfully commercialize Gattex, including the risk that
physicians and patients may not see the advantages of Gattex and may therefore
be reluctant to utilize the product, the risk that private and public payers
may be reluctant to cover or provide reimbursement for Gattex, the risk that
the company may be unable to resolve the manufacturing issue in order to
submit its BLA for Natpara, the risks associated with the company's strategy,
global macroeconomic conditions, the impact of changes in management or staff
levels, the effect of legislation effecting healthcare reform in the United
States, as well as other risk factors described in the company's periodic
filings with the U.S. Securities and Exchange Commission, including its Annual
Report on Form 10-K and Form 10-Qs. All information in this press release is
as of the date of this release and NPS undertakes no duty to update this
information, whether as a result of new information, future events or
otherwise.

Contact:

NPS Pharmaceuticals, Inc.
Susan M. Mesco, 908-450-5516 (office)
smesco@npsp.com
www.npsp.com